Compare LOB & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | VCEL |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2014 | 1996 |
| Metric | LOB | VCEL |
|---|---|---|
| Price | $38.84 | $37.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $42.75 | ★ $57.50 |
| AVG Volume (30 Days) | 305.2K | ★ 386.6K |
| Earning Date | 04-22-2026 | 04-03-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | 3.05 | ★ 385.71 |
| EPS | ★ 1.28 | N/A |
| Revenue | N/A | ★ $237,224,000.00 |
| Revenue This Year | $35.52 | $18.02 |
| Revenue Next Year | $16.03 | $18.52 |
| P/E Ratio | $30.19 | ★ N/A |
| Revenue Growth | N/A | ★ 20.10 |
| 52 Week Low | $22.68 | $29.24 |
| 52 Week High | $42.89 | $55.41 |
| Indicator | LOB | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 51.72 |
| Support Level | $34.63 | $34.61 |
| Resistance Level | $39.16 | $38.41 |
| Average True Range (ATR) | 1.50 | 1.65 |
| MACD | -0.41 | 0.28 |
| Stochastic Oscillator | 36.11 | 74.26 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.